P556: Cyclosporine in acute severe steroid-refractory ulcerative colitis: Short-and long-term outcomesECCO '18 Vienna
2018
P557: Cost-effectiveness of infliximab vs. surgery for severe chronic ulcerative colitis: a Markov analysisECCO '18 Vienna
2018
P558: Golimumab improves patient-reported work productivity and activity impairment in patients with ulcerative colitis: Interim results from a non-interventional trial in GermanyECCO '18 Vienna
2018
P560: Granulocyte–monocyte apheresis combination therapy after loss of response to anti-TNF drugsECCO '18 Vienna
2018
P561: A comparison of medication adherence and persistence between intravenous biologics and oral small-molecule therapiesECCO '18 Vienna
2018
P562: Role, efficacy and safety of budesonide multi-matrix in ulcerative colitis in real life: A study in three Italian third-level centresECCO '18 Vienna
2018
P563: Stopping anti-TNFα monotherapy in Crohn's disease patients in deep remission and favourable disease characteristics is associated with a high rate of relapseECCO '18 Vienna
2018
P564: Indigo naturalis induces mucosal healing in patients with ulcerative colitis: A multicentre randomised controlled trialECCO '18 Vienna
2018
P565: Real-world use of azathioprine metabolites changes clinical management of inflammatory bowel diseaseECCO '18 Vienna
2018
P566: Effect of polyethylene glycol (PEG) bowel preparation on faecal calprotectin levels in patients with ulcerative colitisECCO '18 Vienna
2018
P567: Long-term outcome of perianal fistulae treated with anti-TNFα therapy in a cohort of Saudi patients with Crohn’s disease based on Parks classificationECCO '18 Vienna
2018
P568: The impact of a virtual clinic on clinical decision-making and healthcare resource use vs. standard care: The Oxford experienceECCO '18 Vienna
2018
P569: Outcomes of IBD patients treated with infliximab: The impact of therapeutic drug monitoring in real-life clinical practiceECCO '18 Vienna
2018
P570: Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: Results from GEMINI trial dataECCO '18 Vienna
2018
P572: Reactive dose escalation of infliximab in patients with Crohn’s disease in TAILORIX leads to improved outcomesECCO '18 Vienna
2018
P573: Safety and immune modulatory properties of etrasimod (APD334), a next-generation oral, selective sphingosine 1-phosphate receptor (S1PR) modulator, in healthy volunteersECCO '18 Vienna
2018